Marco Cipolli

Verona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Italian Cystic Fibrosis Registry (ICFR). Report 2023-2024

Italian Cystic Fibrosis Registry (ICFR). Report 2023-2024

Journal: Epidemiologia e prevenzione

Published: June 29, 2026

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment.

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment.

Journal: Journal of patient-reported outcomes

Published: February 13, 2026

Hog1/p38 and ZAKα drive Shwachman-Diamond syndrome and provide targets to improve cell growth.

Hog1/p38 and ZAKα drive Shwachman-Diamond syndrome and provide targets to improve cell growth.

Journal: bioRxiv : the preprint server for biology

Published: February 13, 2026

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR-DRP1 modulation.

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR-DRP1 modulation.

Journal: Cell death discovery

Published: September 15, 2025

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program.

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program.

Journal: Respiratory research

Published: August 19, 2025

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center.

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center.

Journal: Pulmonary therapy

Published: July 29, 2025

Cytogenetics of Shwachman Diamond syndrome: 27 years report of the Italian cohort and review of the literature.

Cytogenetics of Shwachman Diamond syndrome: 27 years report of the Italian cohort and review of the literature.

Journal: European journal of medical genetics

Published: July 16, 2025

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Journal: Frontiers in pharmacology

Published: July 07, 2025

Beyond the bench: Revitalizing ataluren development for rare genetic disorders.

Beyond the bench: Revitalizing ataluren development for rare genetic disorders.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 29, 2025

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Journal: Journal of clinical medicine

Published: April 22, 2025

COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.

COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 31, 2025

Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia.

Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia.

Journal: Cell death discovery

Published: January 21, 2025

Showing 1-12 of 83

Last Updated: 09/26/2026